De Havilland Partners with Avincis to Enhance CL Series Aircraft Services
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 4 day ago0mins
- Collaboration Agreement: De Havilland and Avincis have established a partnership where Avincis transfers its ADS-B and FMS supplemental type certificates for CL aircraft to De Havilland, enhancing the spare parts catalog and improving access to critical system solutions for global CL aircraft operators.
- Market Responsiveness: This collaboration enables De Havilland to better serve Avincis, the largest operator of CL-415 aircraft globally, which is expected to enhance customer satisfaction and strengthen market competitiveness.
- Design and Maintenance Capabilities: Avincis brings over 20 years of operational experience with CL-415 aircraft, providing robust design and maintenance capabilities that will deliver high-quality solutions to global CL aircraft operators, further solidifying its market position.
- Commitment to Ongoing Investment: This partnership is part of De Havilland's ongoing investment and commitment to CL aircraft customers, demonstrating the company's dedication to enhancing its service capabilities in the global aviation market through collaboration with Avincis.
DH.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DH
Wall Street analysts forecast DH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DH is 3.52 USD with a low forecast of 3.00 USD and a high forecast of 4.06 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
2 Buy
4 Hold
1 Sell
Hold
Current: 2.560
Low
3.00
Averages
3.52
High
4.06
Current: 2.560
Low
3.00
Averages
3.52
High
4.06
Canaccord
David Hynes
Hold
downgrade
$5 -> $4
2025-11-10
Reason
Canaccord
David Hynes
Price Target
$5 -> $4
2025-11-10
downgrade
Hold
Reason
Canaccord analyst David Hynes lowered the firm's price target on Definitive Healthcare to $4 from $5 and keeps a Hold rating on the shares. The firm said the positive takeaways here are that new customer acquisition exceeded internal expectations, the firm is making progress on mitigating downsell pressures, and gross revenue retention should be up year-over-year.
Baird
Neutral
downgrade
$4 -> $3
2025-11-07
Reason
Baird
Price Target
$4 -> $3
2025-11-07
downgrade
Neutral
Reason
Baird lowered the firm's price target on Definitive Healthcare to $3 from $4 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
Stifel
Buy
downgrade
$6 -> $5
2025-11-07
Reason
Stifel
Price Target
$6 -> $5
2025-11-07
downgrade
Buy
Reason
Stifel lowered the firm's price target on Definitive Healthcare to $5 from $6 and keeps a Buy rating on the shares. While "encouraged" by management's actions to reaccelerate growth and improve profitability, the firm acknowledges that the stock's valuation reflects the absence of near-term catalysts as the company's turnaround continues.
Baird
Joe Vruwink
Neutral
maintain
$3 -> $4
2025-08-08
Reason
Baird
Joe Vruwink
Price Target
$3 -> $4
2025-08-08
maintain
Neutral
Reason
Baird analyst Joe Vruwink raised the firm's price target on Definitive Healthcare to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results and where its outlook was nudged higher.
See All Ratings
About DH
Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. Its business is conducted through AIDH TopCo, LLC (Definitive OpCo).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to the stock rating improvement for Definitive Healthcare Corp?
How does Kenneth Fisher's Price/Sales model evaluate Definitive Healthcare Corp's performance?
Will the improved stock rating lead to increased investor interest in DH?
How might Definitive Healthcare's stock price change in the next quarter?